Incyte Corporation vs Atlassian Corporation PLC — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Atlassian Corporation PLC trades at $90.93 (market cap $23.67B). The key difference: Incyte Corporation and Atlassian Corporation PLC are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| INCY | TEAM | |
|---|---|---|
Market Cap | $23.11B | $23.67B |
Sector | Health | Technology |
52-Week High | $118.52 | $203.00 |
52-Week Low | $67.38 | $57.15 |
Enterprise Value | $19.13B | $23.78B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →